Select Language

English

Down Icon

Select Country

Spain

Down Icon

ADO invests 2 billion pesos in buses

ADO invests 2 billion pesos in buses

ADO announced an investment of more than 2 billion pesos in the total renewal of its fleet for its Platinum and GL services.

The addition of 303 new units marks the beginning of a new era in the country's land mobility, offering a more comfortable and exclusive transportation option for domestic and international travelers, connecting them from the center to the south of the country.

This renovation reflects ADO's historic vision of putting the passenger at the center, as was the case in 1939 when First Class was introduced in Mexico.

By 2025, ADO plans to add 83 units to the ADO Platino service and 220 units to the ADO GL service. These units will connect more than 50 destinations in the center and south of the country from more than 70 terminals, transporting more than 3 million passengers annually between the two services.

Top Win International plans to launch a voluntary tender offer, along with other bitcoin-focused investors, for up to 11.58% of the common shares and unexercised warrants of DV8 Public Co., a Thai-listed company, through its subsidiary AsiaStrategy Topwin.

The offer price is 56 Thai satangs ($0.02) per share and 1 satang per warrant, Top Win said in a statement on Monday.

The offering is expected to close on August 20.

Top Win shares fell 12% in late trading Monday.

Mustang Bio shares surged nearly 174% on Wall Street on Monday after the U.S. Food and Drug Administration granted orphan drug designation to the company for its MB-101, a drug for the treatment of recurrent diffuse anaplastic astrocytoma and glioblastoma.

The label offers incentives, such as tax credits for the cost of clinical trials after approval and exemptions from prescription drug user fees, the company said.

Preclinical data supported a novel combination of MB-101 and MB-108 to optimize clinical outcomes, according to the company.

The FDA granted Mustang orphan drug designation for MB-108, a drug for the treatment of malignant glioma.

US tech giant Apple is appealing a €500 million ($587 million) fine imposed by the European Union for violating the bloc's so-called Digital Markets Act.

The European Commission fined the Cupertino, California-based company for leveraging its dominant market position to impose restrictions on software developers using its platform, resulting in consumer harm.

"As our appeal will show, the European Commission is imposing commercial terms that confuse developers and harm users," Apple said.

[email protected]

Eleconomista

Eleconomista

Similar News

All News
Animated ArrowAnimated ArrowAnimated Arrow